Can Lyrica (pregabalin) be used to treat post‑stroke neuropathic pain in an adult patient?

Can Lyrica Be Used in Post-Stroke Neuropathy?

Lyrica (pregabalin) can be used for post-stroke neuropathic pain, but only as a second-line treatment after amitriptyline and lamotrigine have failed or are not tolerated. The evidence shows mixed efficacy for pain reduction, though it may help with associated sleep disturbances and anxiety 1.

Treatment Algorithm for Post-Stroke Neuropathic Pain

First-Line Therapy

Start with amitriptyline 75 mg at bedtime or lamotrigine (titrated to therapeutic dose). These are the only medications with Class IIa (reasonable first-line) recommendations from the American Heart Association/American Stroke Association guidelines 1.

• Amitriptyline: Proven to lower daily pain ratings and improve global functioning
• Lamotrigine: Reduces daily pain and cold-induced pain, though only 44% of patients achieve good clinical response

Second-Line Therapy (When First-Line Fails)

Pregabalin may be considered as a Class IIb recommendation (second-line treatment) 1. The guidelines explicitly state: "Pregabalin, gabapentin, carbamazepine, or phenytoin may be considered as second-line treatments."

Critical Evidence About Pregabalin's Efficacy

The Reality Check

Two clinical trials found that pregabalin was NOT significantly better than placebo for reducing daily pain in central post-stroke pain 1, 2. A major 2011 randomized controlled trial of 219 patients showed:

• Baseline pain score: 6.5 (pregabalin) vs 6.3 (placebo)
• Endpoint pain score: 4.9 (pregabalin) vs 5.0 (placebo)
• No significant difference (P=0.578) 2

Where Pregabalin May Help

Despite poor pain efficacy, pregabalin showed benefits in:

• Sleep improvement (MOS-sleep scores)
• Anxiety reduction (HADS-A anxiety scores)
• Clinician global impression of change 2

The guidelines acknowledge: "Sleep and anxiety were improved with pregabalin, however" 1.

Practical Prescribing Guidance

When to Consider Pregabalin

Use pregabalin in post-stroke neuropathic pain when:

1. Amitriptyline and lamotrigine have failed or caused intolerable side effects
2. The patient has significant sleep disturbances or anxiety related to their pain
3. You need an alternative to tricyclic antidepressants in elderly patients with cardiac contraindications

Dosing Strategy

• Start: 150 mg/day in 2-3 divided doses
• Titrate: To 300 mg/day after 1-2 weeks
• Maximum: 600 mg/day (though higher doses show more side effects without consistently better pain relief) 3
• Trial duration: Allow 4 weeks at therapeutic dose before declaring treatment failure 3

FDA Approval Status

Important caveat: While the FDA has approved Lyrica for multiple neuropathic pain conditions (diabetic neuropathy, postherpetic neuralgia, spinal cord injury neuropathic pain), central post-stroke pain is NOT specifically listed as an FDA-approved indication 4. This represents off-label use.

Safety Considerations

Common Side Effects

Expect these in the majority of patients 4:

• Dizziness (15-29% depending on dose)
• Somnolence (12-16%)
• Peripheral edema (up to 12%)
• Weight gain (up to 6%)
• Blurred vision (up to 6%)

Discontinuation Rates

In post-stroke pain trials, 14% of pregabalin patients discontinued due to adverse effects compared to 7% on placebo 4. Most common reasons: dizziness (4%) and somnolence (3%).

Special Warnings

• Avoid abrupt discontinuation: Taper to prevent withdrawal symptoms (headaches, nausea, increased sweating, anxiety)
• Renal dosing required: Adjust for creatinine clearance
• Schedule V controlled substance: Has abuse potential
• Driving impairment: Warn patients about dizziness and somnolence affecting ability to operate machinery

Combination Therapy Approach

Combine pregabalin with therapeutic exercise and psychosocial support for optimal outcomes 1. The guidelines recommend interprofessional pain management as Class IIa evidence.

One case report showed promising results combining pregabalin with transcutaneous electrical nerve stimulation (TENS) for post-stroke neuropathic pain, though TENS alone is ineffective 5.

Monitoring Treatment Response

Use standardized measures 1:

• Pain diaries
• Visual analog scales (VAS)
• Pain questionnaires (e.g., Short-Form McGill Pain Questionnaire)

Reassess at 1.5 months and 3 months to determine if continuing therapy is warranted.

Bottom Line

Start with amitriptyline or lamotrigine first. Only move to pregabalin if these fail or cause intolerable side effects. Set realistic expectations: pregabalin may not significantly reduce pain intensity but could improve sleep and anxiety, which may be valuable for overall quality of life in stroke patients. The treatment choice should be individualized based on the patient's comorbidities, side effect profile tolerance, and whether sleep/anxiety symptoms are prominent features alongside their neuropathic pain.